Smartsheet alternatives: AI program tracking for biotech

The tools people actually move to are named below, with what each one is. Then the question the list does not answer, which on a drug development program is usually the one that matters.

The tools people move to

Each line is what the vendor says its own product is, read off its own site. It is not a ranking. These products overlap heavily and the choice between them is mostly a question of shape.

Notion belongs on the same shortlist for the document-first shape, and gets its own treatment in Notion for biotech. Nothing on that list is a mistake to buy. Pick by shape: a task graph, a database, or a workspace.

What none of them changes

Smartsheet is good, which is the part nobody writing an alternatives list bothers to say. Timeline, grid, card, Gantt and calendar views over the same sheet, automated workflows for updates, approvals and notifications, portfolio rollups, resource management, request intake, dashboards. Its AI layer answers questions in context over your own sheets, summarizes across rows in bulk, and builds a dashboard from a plain description. Its own page names Claude, Microsoft Copilot, Google Gemini and ChatGPT as tools you can point at your live work.

Now the thing the whole table has in common. A row is exactly as true as the last person who typed in it. That is not a criticism, it is the definition, and every product above inherits the same physics. Swapping between them changes the invoice, the view and the onboarding, and it does not change who has to type.

On a drug development program the untyped facts are the expensive ones. The integrated timeline is only as good as the moment somebody moves the bar, and the moment somebody moves the bar is usually two weeks after the fact that moved it.

What that looks like on an IND-enabling program

A director of program management is driving a lead candidate to its IND. Toxicology is at a contract research organization, analytical method development is at a second vendor, and the internal chemistry and regulatory leads report into a monthly review.

On the eighteenth both vendors send their monthly deliverable logs, and the purchase order ledger arrives with them. Neither is matched to the baseline the plan was built on. The grid still shows the baseline, because the baseline is what somebody typed. Which deliverables were accepted, which slipped, and what that does to the critical path is a reconciliation nobody has done, and the review pack is due. The risk log has an entry from four months ago about the dependency those logs would settle, logged once, never revisited.

Nothing there is hard. All of it is invisible unless somebody opens the tracker and types. And the person who would type it is building next week's review pack, is chasing two other vendors, and has not opened either export. That is the actual failure: not the tool, the typing.

What an AI agent does differently

The other shape is a single-seat system installed for one person on their own machine, in plain files that person owns. It reads the mail they already receive and the transcripts they already generate. When those exports land, it maps each deliverable in them onto the baseline, recomputes the critical path from what was actually accepted rather than what was planned, and writes the first draft of the schedule section of the review pack, showing the position it found rather than the one the grid was last told about. Where a deliverable slipped, getting the reason out of the vendor becomes the program director's own follow-up, and the note asking for it is drafted rather than sent.

Three honest limits. It is single-seat, installed for the program director and not the function leads, and it never assigns anyone else a task; someone else's commitment becomes the buyer's own item to check. Cadence is hourly at best, not instant. And it is not a shared workspace: if ten people need to co-edit one plan, that is what the table is for.

Which problem do you have

If several people need to edit and see one plan, buy from the table; that is exactly what those products are for. If the plan is right and only the views are wrong, buy from the table too, and pick on shape. But if the plan is stale because one person has to maintain it, or the facts live in mail and calls and never reach the plan, the tool is not the constraint.

If your question is really whether to buy at all, the decision page is build or buy biotech project management software. If it is about the function rather than the tool, AI for program management in drug development covers the same ground from the job's side. If the documents you track are regulated rather than operational, read Veeva Vault alternatives first. If the problem is finding things rather than keeping them current, that is Glean alternatives. And the full comparison of biotech software alternatives puts the four incumbents together.